纳武利尤单抗和帕博利珠单抗治疗复发性或转移性头颈部鳞状细胞癌药物经济学系统性评价

Systematic evaluation of economic evaluations of Nivolumab and Pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma

目的:系统回顾纳武利尤单抗和帕博利珠单抗治疗复发性或转移性头颈部鳞癌的药物经济学研究。方法:通过检索中国知网、PubMed、Web of Science等数据库,纳入符合标准的研究,分析纳入研究的视角、时限、数据来源、模型等关键要素,并使用CHEERS和Philips量表对纳入研究进行评估,量化评估研究的完整性和质量。结果:共纳入13项研究,纳入研究选取的数据来源、模型、时限、成本等因素存在不同之处,不同研究得出的结论也存在一定差异。帕博利珠单抗的相关研究得出的结论一致性较低,纳武利尤单抗的相关研究得出的结论一致性相对较高。CHEERS和Philips量表评估结果表示目前研究质量仍有提高空间。结论:现有研究得出的结果和结论并不一致,但大多数研究表明,帕博利珠单抗或纳武利尤单抗不是一种经济性的用药方案。现有研究中选取的临床数据、模型构建、研究时限、成本、阈值等关键要素的不同导致研究结果和结论存在差异。

OBJECTIVE This study systematically reviewed pharmacoeconomic studies of nivolumab and pembrolizumab for the treatment of recurrent or metastatic head and neck squamous carcinoma.METHODS Studies that met the criteria were included by searching CNKI,PubMed,and Web of Science databases,analyzing key elements such as perspective,time frame,data sources,and models of the included studies,and assessing the included studies using the CHEERS and Philips checklists to quantify the completeness and quality of the studies.RESULTS A total of 13 studies were included,and there were differences in the data sources,models,time horizon,costs,and other factors selected for the studies,and some differences in the conclusions reached by different studies.the consistency of the conclusions reached by the studies related to pembrolizumab was low,while the consistency of the conclusions reached by the studies related to nivolumab was relatively high.the results of the CHEERS and Philips checklists assessment indicated that there is still room for improvement in the quality of the current studies.CONCLUSION The available studies did not reach consistent results and conclusions,but most of them suggested that pembrolizumab or nivolumab was not an economical dosing regimen.Differences in clinical data,model construction,study timelines,costs,thresholds,and other key elements led to differences in study results and conclusions.